<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441738</url>
  </required_header>
  <id_info>
    <org_study_id>NL.52951.068.16</org_study_id>
    <nct_id>NCT02441738</nct_id>
  </id_info>
  <brief_title>Hybrid Versus Catheter Ablation in Persistent AF</brief_title>
  <acronym>HARTCAP-AF</acronym>
  <official_title>Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation Versus Transvenous Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia with a lifetime risk of&#xD;
      developing AF of 1 in 4 people aged over 40. Besides hemodynamic compromises stroke remains&#xD;
      the most feared complication of AF with an increase in risk by 5-fold.&#xD;
&#xD;
      Catheter ablation has evolved as a standardized treatment option in paroxysmal AF. Due to the&#xD;
      advanced electrical and structural remodeling the single procedural results of catheter&#xD;
      ablation for persistent and longstanding persistent AF are rather disappointing without a&#xD;
      proven superiority of any applied strategy compared to others. However, repeated catheter&#xD;
      ablation can achieve better results. The surgical (epicardial) approach seems to be more&#xD;
      effective, though still a significant amount of failures exist. Checking the epicardial&#xD;
      ablation lines and if necessary making additional endocardial lines (which is a hybrid&#xD;
      ablation) is expected to be most efficacious in avoiding lesion gaps and providing the most&#xD;
      complete lesion set.&#xD;
&#xD;
      The study objective of this pilot trial is to compare the safety and efficacy of catheter&#xD;
      ablation within 6 months versus a hybrid ablation consisting of endoscopic epicardial surgery&#xD;
      combined with endocardial catheter ablation (performed one-stage) in preventing the&#xD;
      recurrence of atrial fibrillation (AF) in symptomatic, drug refractory patients with&#xD;
      persistent or longstanding persistent atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2016</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from any AT off antiarrhythmic drugs class I or III lasting &gt; 5 minutes after the blanking period, evaluated by any ECG-tracing and 7-day holter.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications during follow-up</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Hybrid Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hybrid Ablation</intervention_name>
    <description>The procedure will be performed following standard of care guidelines.</description>
    <arm_group_label>Hybrid Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>The procedure will be performed following standard of care guidelines.</description>
    <arm_group_label>Catheter Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known with a history of symptomatic persistent AF or longstanding persistent atrial&#xD;
             fibrillation,&#xD;
&#xD;
          -  Refractory to or intolerant of at least one antiarrhythmic drug class I or III,&#xD;
&#xD;
          -  At least 18 years of age,&#xD;
&#xD;
          -  Mentally able and willing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ablation procedure,&#xD;
&#xD;
          -  Longstanding persistent AF &gt; 3 years,&#xD;
&#xD;
          -  Paroxysmal atrial fibrillation. Successful cardioversion within 48 hours of onset of&#xD;
             the arrhythmia will be also considered paroxysmal. In patients with paroxysmal and&#xD;
             persistent AF, the dominant pattern should be taken to categorize,&#xD;
&#xD;
          -  Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or other&#xD;
             reversible or non-cardiovascular cause,&#xD;
&#xD;
          -  Presence of left atrial appendage (LAA) thrombus,&#xD;
&#xD;
          -  Left atrial size ≥ 60mm (PLAX-view on TEE),&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40%,&#xD;
&#xD;
          -  In need for other cardiac surgery then AF treatment within 12 months,&#xD;
&#xD;
          -  Intolerance to heparin and warfarin,&#xD;
&#xD;
          -  Unable to undergo TEE,&#xD;
&#xD;
          -  Sick-sinus-syndrome&#xD;
&#xD;
          -  Mitral valve insufficiency &gt; Iº&#xD;
&#xD;
          -  Carotic stenosis &gt; 80%,&#xD;
&#xD;
          -  Active infection or sepsis,&#xD;
&#xD;
          -  Pleural adhesions,&#xD;
&#xD;
          -  Elevated hemi diaphragm&#xD;
&#xD;
          -  Significant pulmonary dysfunction as assessed by preoperative lung testing,&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease with a FEV1 or VC &lt; 50% predicted&#xD;
&#xD;
          -  History of cerebrovascular accident (CVA) or transient ischemic attack (TIA),&#xD;
&#xD;
          -  History of blood clotting abnormalities,&#xD;
&#xD;
          -  History of thoracic radiation,&#xD;
&#xD;
          -  History of pericarditis,&#xD;
&#xD;
          -  History of cardiac tamponade,&#xD;
&#xD;
          -  History of thoracotomy or cardiac surgery,&#xD;
&#xD;
          -  Body-mass-index &gt; 40,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Life expectancy less than 12 months,&#xD;
&#xD;
          -  Participation in any other clinical study involving an investigational drug or device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Pison, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark La Meir, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Hybrid Ablation</keyword>
  <keyword>Catheter Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

